New developments in the standardization of total prostate-specific antigen

Clinical Biochemistry

Volumn 32, Issue 8, 1999, Pages 627-634

  Blijenberg, Bert G ^a   Storm, B E R T N ^a   Van Zelst, Bertrand D ^a   Boeken Kruger, Arto E ^b   Schröder, Fritz H ^b  

^a Department of Clinical Chemistry ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANALYTIC METHOD; ANTIGEN DETECTION; ARTICLE; CALIBRATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; STANDARDIZATION; VALIDATION PROCESS;

CALIBRATION; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SEMEN;

EID: 0033451939     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(99)00074-0     Document Type: Article

References (37)

1. Seamonds B., Yang N., Anderson K., Whitaker B., Shaw L.M., Bollinger J.R. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology. 28:1986;472-479.
2. Siddall J.K., Cooper E.H., Newling D.W.W., Robinson M.R.G., Whelan P. An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. Eur Urol. 12:1986;123-130.
3. van Dieijen-Visser M.P., Delaere K.P.J., Gijzen A.H.J., Brombacher P.J. A comparitive study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland. Clin Chim Acta. 174:1988;131-140.
4. Oesterling J.E. Prostate-specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate . J Urol. 145:1991;907-923.
5. Bogdanowicz J.F.A.T., Bentvelsen F.M., Oosterom R., Schrd̈er F.H. Evaluation of prostate-specific antigen and prostatic phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. Scand J Urol Nephrol. 138:1991;97-103.
6. Lowe F.C., Trauzzi S.J. Prostatic acid phosphatase in 1993 its limited clinical utility . Urol Clin North Am. 20:1993;589-595.
7. Chan D.W., Bruzek D.J., Oesterling J.E., Rock R.C., Walsh P.C. Prostate-specific antigen as a marker for prostatic cancer a monoclonal and a polyclonal immunoassay compared . Clin Chem. 33:1987;1916-1920.
8. Hortin G.L., Bahnson R.R., Daft M., Chan K.-M., Catalona W.J., Ladenson J.H. Differences in values obtained with 2 assays of prostate-specific antigen. J Urol. 139:1988;762-765.
9. Graves H.C.B., Wehner N., Stamey T.A. Comparison of a polyclonal and a monoclonal immunoassay for PSA need for a international antigen standard . J Urol. 144:1990;1516-1522.
10. Turkes A., Nott J.P., Griffiths K. Prostate-specific antigen problems in analysis . Eur J Cancer. 27:1991;650-652.
11. Semjonow A., Brandt B., Oberpenning F., Roth S., Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific values. The Prostate Suppl. 7:1996;3-16.
12. Stamey T.A. Second Stanford conference on international standardization of prostate-specific antigen assays September 1 and 2, 1994 . Urology. 45:1995;173-184.
13. Murphy G.M. The second Stanford conference on international standardization of prostate-specific assays. Cancer. 75:1995;122-128.
14. Nakamura R.M. Current status and future directions in standardization of prostate-specific antigen immunoassay. Urology. 51:(Suppl. 5A):1998;83-88.
15. Segurado O.G., Volmer W., Dowell B. PSA standardization a review of NCCLS, Stanford and Abbott efforts . Anticancer Res. 17:1997;2919-2920.
16. Graves H.C.B. Prostate-specific antigen comes of age in diagnosis and management of prostate cancer. Clin Chem. 38:1992;1930-1932.
17. Stenman U.-H., Leinonen J., Zhang W.-M. Problems in the determination of prostate-specific antigen. Eur J Clin Chem Clin Biochem. 34:1996;735-740.
18. Auvinen A, Calais da Silva F, Denis LJ, Hugosson J, Schröder FH. The European Randomized Study of Screening for Prostate Cancer (ERSPC): international cooperation and preliminary data. In: Schröder FH, Ed. Recent advantages in prostate cancer and BPH. Proceedings of the Fourth Congress on Progress and controversies in Oncological Urology. 1996 April; Rotterdam. New York: Parthenon Publishing Group, 1997:167-73.
19. Schröder FH, Bangma CH. The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol 1997; (Suppl 1): 68-71.
20. Passing H., Bablok W. A new biomedical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem. 21:1983;709-720.
21. Passing H., Bablok W. Comparison of several regression procedures for method comparison studies and determination of sample sizes. Application of linear regression studies in clinical chemistry. Part II. J Clin Chem Clin Biochem. 22:1984;31-45.
22. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. i:1986;307-310.
23. Hollis S. Analysis of method comparison studies. Ann Clin Biochem. 33:1996;1-4.
24. Wu J.T. Assay for prostate-specific antigen (PSA) problems and possible solutions . J Clin Lab Anal. 8:1994;8-12.
25. Graves H.C.B. Standardization of immunoassays for prostate-specific antigen. Cancer. 72:1993;3141-3144.
26. Graves H.C.B. Issues on standardization of immunoassays for prostate-specific antigen a review . Clin Invest Med. 16:1993;415-424.
27. Stenman U.-H., Leinonen J., Zhang W.-M. Standardization of PSA determinations. Scand J Clin Lab Invest. 55:(Suppl 221):1995;45-51.
28. Sokoloff R.L., Wolfert R.L., Rittenhouse H.G. Standardization of PSA assays proposals and practical limitations . J Clin Ligand Assay. 18:1995;86-92.
29. Vessella R.L. Issues in the assessment of prostate-specific antigen immunoassays. Urol Clin North Am. 24:1997;261-268.
30. Zhang W.-M., Leinonen J., Kalkkinen N., Dowell B., Stenman U.-H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem. 41:1995;1567-1573.
31. Corey E., Wegner S.K., Stray J.E., et al. Characterization of 10 new monoclonal antibodies against prostate-specific antigen by analysis of affinity, specificity and function in sandwich assays. Int J Cancer. 71:1997;1019-1028.
32. Frenette G., Gervais Y., Tremblay R.R., Dube J.Y. Contamination of purified prostate-specific antigen preparations by kallikrein hK2. J Urol. 159:1998;1375-1378.
33. Stamey T.A., Chen Z., Prestigiacomo A.F. Reference material for PSA the IFCC Standardization Study . Clin Biochem. 31:1998;475-481.
34. Mitrunen K., Pettersson K., Piironen T., Bjork T., Lilja H., Lövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem. 41:1995;1115-1120.
35. Blankenstein M.A., Van Zon J. Recognition of free prostate-specific antigen (PSA) and PSA-ACT complex by different assays. Anticancer Res. 15:(Suppl):1995;2398-2399.
36. Garg U.C., Howanitz J.H., Nakamura R.M., Plous R.H., Eckfeldt J.H. Production, analysis, and characterization of reference materials for prostate-specific antigen. Arch Pathol Lab Med. 119:1995;1104-1108.
37. Tewari P.C., Williams J.S. Analytical characteristics of seminal fluid PSA differ from those of serum PSA. Clin Chem. 44:1998;192-192.